Stereotaxis to Acquire Robocath for Up to $45M

Stereotaxis, Inc. has entered into a Share Sale Agreement to acquire 100% of Robocath, a French innovator in advanced mechanical robotic technology for interventional cardiology and neurointerventions. The initial consideration for the acquisition is $20.0 million, payable in cash, Stereotaxis common stock (valued at $2.00 per share), or a combination. Additionally, Robocath shareholders could receive up to $25 million in earnout payments if certain performance targets are met. The acquisition is subject to various closing conditions and is expected to finalize in July 2026, aiming to expand Stereotaxis's robotic technology portfolio.